Lifeward Ltd., a leader in innovative medical technology, announced the successful closing of its public offering, raising approximately $2.6 million. The offering included 4,000,000 ordinary shares and accompanying warrants to purchase an equal number of shares at $0.65 each. The warrants are immediately exercisable and expire in five years. H.C. Wainwright & Co. served as the exclusive placement agent. The proceeds will support Lifeward's commercial efforts, working capital, and general corporate purposes.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。